The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory CommitteeElı́as Campo, Andrew D. Zelenetz, Ari Melnick et al.|Blood|2022Cited by 1.5k
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium ProgramShimin Hu, Ken H. Young, Govind Bhagat et al.|Blood|2013Cited by 677
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program StudyZijun Y. Xu‐Monette, Ken H. Young, Lin Wu et al.|Blood|2012Cited by 390
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program StudyShimin Hu, Ken H. Young, Zijun Y. Xu‐Monette et al.|Blood|2013Cited by 246
CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1− mantle cell lymphomaDavid Martin‐García, Sı́lvia Beà, Alba Navarro et al.|Blood|2018Cited by 112